Frequency of Barrett’s neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study

Background: Barrett’s adenocarcinoma is being diagnosed increasingly. We examine possible differences between long segment and short-segment Barrett esophagus (LSBE and SSBE) in long-term follow-up on the basis of our histopathology registry.
Methods and patients: All Barrett’s esophagus patients diagnosed histologically between 1990 and 1995 (n = 1071) were selected. Long-term follow-up data from endoscopy with biopsy were sought on all patients without neoplasia on initial endoscopic biopsy (n = 1003). A total of 255 individuals (25.4 %) were regarded as drop-outs (201 lost and 54 without further endoscopy). Of the remaining 748 patients with follow up for more than 5 years, 315 had documented LSBE, 246 had SSBE, and 187 had no length of Barrett esophagus recorded (NLBE).
Results: In the study cases (male : female ratio 2.1 : 1, mean age ± SD 60.9 ± 14.2 years), the biopsy procedure was fully compliant with guidelines in only 32.5 %. Only 5 cases (0.6 %) had visible lesions reported on endoscopy, but all were negative for neoplasia. Over a mean follow-up of 78.2 ± 35.6 months (range 0-240), 7 new cases of low grade intraepithelial neoplasia (LGIN) and 15 cancer cases developed, accounting for a yearly incidence of 0.2 % (LGIN) or 0.4 % (cancer) after an initial negative endoscopy. When the cases with initial diagnosis of neoplasia were included, this yearly incidence rose to 0.5 % (LGIN), 0.3 % (high grade intraepithelial neoplasia [HGIN]) or 1.7 % (cancer). Differences between SSBE and LSBE were only encountered for cancer incidence.
Conclusion: The yearly incidence of Barrett esophagus cancer varies between 0.4 % and 1.7 %. Despite the limitations of this retrospective and pathology-based study, the observed risk of developing cancer in Barrett esophagus without neoplasia is comparable to that found in other studies, mainly from the US and the UK, and varies between 0.7 % and 1.0 % of yearly incidence.

References

• 1 Murray L, Watson P, Johnston B. et al . Risk of adenocarcinoma in Barrett’s oesophagus: population based study.  BMJ. 2003;  327 534-535
• 2 Hongo M, Shoji T. Epidemiology of reflux disease and CLE in East Asia.  J Gastroenterol. 2003;  38 25-30
• 3 Gerson L B, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals.  Gastroenterology. 2002;  123 461-467
• 4 Bytzer P, Christensen P B, Damkier P. et al . Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study.  Am J Gastroenterol. 1999;  94 86-91
• 5 Pera M, Cameron A J, Trastek V F. et al . Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.  Gastroenterology. 1993;  104 510-513
• 6 Bollschweiler E, Wolfgarten E, Gutschow C. et al . Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.  Cancer. 2001;  92 549-555
• 7 Haggitt R C. Adenocarcinoma in Barrett’s esophagus: a new epidemic?.  Hum Pathol. 1992;  23 475-476
• 8 Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus.  N Engl J Med. 1985;  313 857-859
• 9 Hameeteman W, Tytgat G N, Houthoff H J, van den Tweel J G. Barrett’s esophagus: development of dysplasia and adenocarcinoma.  Gastroenterology. 1989;  96 1249-1256
• 10 Conio M, Blanchi S, Lapertosa G. et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.  Am J Gastroenterol. 2003;  98 1931-1939
• 11 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?.  Gastroenterology. 2000;  119 333-338
• 12 Jankowski J A, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the west.  Gastroenterology. 2002;  122 588-590
• 13 Gerson L B, Triadafilopoulos G. Screening for esophageal adenocarcinoma: an evidence-based approach.  Am J Med. 2002;  113 499-505
• 14 Rex D K, Cummings O W, Shaw M. et al . Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn.  Gastroenterology. 2003;  125 1670-1677
• 15 Montgomery E, Bronner M P, Goldblum J R. et al . Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.  Hum Pathol. 2001;  32 368-378
• 16 Ormsby A H, Petras R E, Henricks W H. et al . Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.  Gut. 2002;  51 671-676
• 17 Lagergren J, Bergstrom R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.  N Engl J Med. 1999;  340 825-831
• 18 Sampliner R E;. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 1888-1895
• 19 Spechler S J. Clinical practice. Barrett’s esophagus.  N Engl J Med. 2002;  346 836-842
• 20 Hamilton S R, Aaltonen L A (eds).. WHO Classification. Tumours of the digestive system. Lyon; IARC Press 2000: 20
• 21 El-Serag H B, Aguirre T V, Davis S. et al . Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus.  Am J Gastroenterol. 2004;  99 1877-1883
• 22 Hillman L C, Chiragakis L, Shadbolt B. et al . Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus.  Med J Aust. 2004;  180 387-391
• 23 Koop H, Schepp W, Müller-Lissner S. et al . Consensus conference of the DGVS on gastroesophageal reflux.  Z Gastroenterol. 2005;  43 163-164
• 24 Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett’s oesophagus.  Dig Dis. 2004;  22 171-180
• 25 Csendes A, Smok G, Burdiles P. et al . Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux.  Dis Esophagus. 2003;  16 24-28
• 26 Inadomi J M, Sampliner R, Lagergren J. et al . Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.  Ann Intern Med. 2003;  138 176-186
• 27 Ferguson M K, Durkin A. Long-term survival after esophagectomy for Barrett’s adenocarcinoma in endoscopically surveyed and nonsurveyed patients.  J Gastrointest Surg. 2002;  6 29-35
• 28 Incarbone R, Bonavina L, Saino G. et al . Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett’s esophagus.  Surg Endosc. 2002;  16 263-266
• 29 vanSandick J W, vanLanschot J J, Kuiken B W. et al . Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma.  Gut. 1998;  43 216-222